BERGENBIO MEETS EFFICACY ENDPOINT for FIRST STAGE OF PHASE II TRIAL WITH AXL INHIBITOR BEMCENTINIB IN COMBINATION WITH KEYTRUDA[®] IN NSCLC PATIENTS PROGRESSING ON IMMUNE CHECKPOINT INHIBITORS
(WorldNews Norway)

BERGENBIO MEETS EFFICACY ENDPOINT for FIRST STAGE OF PHASE II TRIAL WITH AXL INHIBITOR BEMCENTINIB IN COMBINATION WITH KEYTRUDA[®] IN NSCLC PATIENTS PROGRESSING ON IMMUNE CHECKPOINT INHIBITORS · First stage clinical efficacy endpoint met for the Phase II trial cohort evaluating selective AXL inhibitor bemcentinib in combination with Keytruda[®] in patients with advanced NSCLC who have failed checkpoint inhibitor therapy. · Criteria were met for expansion of this cohort to a second stage. Bergen, Norway, 15 January 2019 - BerGenBio ASA (OSE: BGBIO) a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces meeting...